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The mammalian immune system discriminates be-
tween modes of cell death; necrosis often results in
inflammation and adaptive immunity, whereas apo-
ptosis tends to be anti-inflammatory and promote
immune tolerance. We have examined apoptosis for
the features responsible for tolerance; specifically,
we looked at the roles of caspases andmitochondria.
Our results show that caspase activation targeted the
mitochondria to produce reactive oxygen species
(ROS), which were critical to tolerance induction by
apoptotic cells. ROS oxidized the potential danger
signal high-mobility group box-1 protein (HMGB1)
released from dying cells and thereby neutralized
its stimulatory activity. Apoptotic cells failed to
induce tolerance and instead stimulated immune
responses by scavenging or bymutating amitochon-
drial caspase target protein when ROS activity was
prohibited. Similarly, blocking sites of oxidation in
HMGB1 prevented tolerance induction by apoptotic
cells. These results suggest that caspase-orches-
trated mitochondrial events determine the impact of
apoptotic cells on the immune response.
INTRODUCTION
The impact of dying cells on the immune system depends on the
manner in which cells die, and the current perception is that
necrotic cells act as ‘‘danger’’ signals, whereas apoptotic cells
are ‘‘silent.’’ For adaptive immune responses, many studies
have documented the immunogenic activity of necrotic cells
and the tolerogenic influence of apoptotic cells (Chen et al.,
2001; Ferguson et al., 2002; Griffith et al., 2007; Griffith et al.,
1996; Kurts et al., 1998; Sauter et al., 2000). Other studies
have shown, however, that in some cases apoptotic cells can
be immunogenic and that this might depend in part on the induc-
ing stimulus (Ronchetti et al., 1999) (Tesniere et al., 2008). Under-
standing this dynamic depends on discovering the factors that
dying cells produce to mediate these effects.The effect of dying cells on the adaptive immune response
traces to their effects on dendritic cells (DCs). This is of particular
importance because it is now clear that apoptotic cells are not
passive participants. Antigens associated with engulfed dying
cells are channeled into the exogenous pathway of class I major
histocompatibility complex (MHC) presentation for stimulation
of CD8+ T cells (Blachere et al., 2005; Dudziak et al., 2007;
Ferguson et al., 2002; Steinman et al., 2003). Apoptotic cells,
for the most part, fail to stimulate presentation to CD4+ T cells
(Griffith et al., 2007). Production of interleukin 10 (IL-10) (Gao
et al., 1998; Tomimori et al., 2000) and/or transforming growth
factor b (TGFb) (Chen et al., 2001) by apoptotic lymphocytes
has been noted, and although it is unlikely that all apoptotic cells
produce these cytokines, it is possible that macrophages and/
or other phagocytic cells produce them in response to apopto-
tic bodies (Fadok et al., 1998; Ronchetti et al., 1999). One dis-
tinction between apoptotic and necrotic cells is the production
of danger signals from the latter. For example, the DNA-binding
protein HMGB1 has been reported to be preferentially released
from necrotic but not apoptotic cells (Scaffidi et al., 2002) and
potently acts on DCs to promote immunity (Dumitriu et al.,
2005). However, several recent studies have questioned the
preferential release of HMGB1 from necrotic cells (Bell et al.,
2006; Choi et al., 2004; Obeid et al., 2007a; Tian et al.,
2007). Other mediators, such as uric acid (Shi et al., 2003), cal-
reticulin (Obeid et al., 2007a; Obeid et al., 2007b), and HSP70
(Millar et al., 2003), can also stimulate the immunological
response.
A major distinction between apoptosis and other forms of cell
death is the involvement of caspase proteases (Martin and
Green, 1995). These enzymes are activated by signaling path-
ways in the apoptotic cells and orchestrate apoptosis through
their cleavage of specific substrates. Although often not required
for cell death per se (Chipuk and Green, 2005), they are important
for many of the cellular events associated with apoptosis; such
events include DNA fragmentation, membrane blebbing, and
fragmentation of the cell into membrane-bound apoptotic bod-
ies (Taylor et al., 2008). Importantly for our discussion, inhibition
of caspases by the use of pharmacologic agents (Ferguson et al.,
2002) or viral proteins (Chen et al., 2006) during cell death con-
verted the tolerogenic signals provided by apoptotic cells into
immunogenic ones. Therefore, caspase substrates or someImmunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc. 21
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duction by apoptotic cells.
The mitochondrial pathway of apoptosis is induced by a wide
variety of stimuli that engage B cell lymphoma protein 2 (Bcl-2)
family members that affect permeablization of the outer mem-
branes of the mitochondria. This mitochondrial outer membrane
permeablization (MOMP) results in the release of cytochrome c
into the cytosol and triggers the activation of the executioner
caspases 3 and 7 (Bonfoco et al., 1998). Activated caspases
then feed back on the permeable mitochondria and cleave a
mitochondrial substrate, NADH dehydrogenase Fe-S protein-1
(p75 NDUSF1), the 75 kDa subunit of respiratory complex I and
a component of the electron transport chain. As a result, electron
transport halts, and ROS are produced in abundance (Ricci et al.,
2004). We had previously observed that B cell leukemia/lym-
phoma x long (Bcl-xL), which blocks MOMP and the mitochon-
drial pathway of apoptosis, prevents tolerance induction by
apoptotic lymphocytes, even when apoptosis is induced by
a pathway (Fas-Fas-ligand) (Griffith et al., 1996) that does not
require MOMP for apoptosis (Huang et al., 1999). This led us to
speculate that some aspect of MOMP, in addition to caspase
activation, might be necessary for the tolerogenic effects of
apoptotic cells on the immune system.
ROS produced by the mitochondria can be involved in cell
death. These toxic compounds are normally detoxified by the
cell; however, during apoptosis ROS produced in the mitochon-
dria participate in the apoptotic process (Fleury et al., 2002).
Recently it was shown that caspase activity against mitochon-
drial complex I of the electron transport system led to increased
ROS production during mitochondrial mediated cell death (Ricci
et al., 2004). ROS can modify cellular components and destroy
their functions (Ott et al., 2007), so we reasoned that ROS might
also affect apoptotic cell components involved in tolerance and
immunity. In this paper we utilize a well-established system of
tolerance induction to examine the consequences of mitochon-
drial changes mediated by caspases. Our results show that
blocking caspase activity at mitochondrial complex I converted
tolerogenic apoptotic cells into immunogens. We further demon-
strate that the caspase-dependent production of ROS during
apoptosis was responsible for destroying immunogenic signals
released from dying cells. Thus, caspase-mediated events lead
to the destruction of potential danger signals that might stimulate
unwanted immunological responses.
RESULTS
Executioner Caspases Are Required for Induction
of Immunological Tolerance by Apoptotic Cells
To study what it is about apoptotic cells that influences the adap-
tive immunological response, we employed a system we have
used extensively (Battisto and Bloom, 1966; Ferguson et al.,
2003; Griffith et al., 2007). Cells (syngeneic, allogeneic, or xeno-
geneic) are coupled with hapten (trinitrophenol, TNP) and in-
jected intravenously, or uncoupled apoptotic cells are fed to
hapten-modified DCs, which in turn are injected intravenously.
So that priming (immunogenicity) can be assessed, animals are
challenged 5 days later in the footpad with the antigen. Alterna-
tively, so that tolerance induction (tolerogenicity) can be as-
sessed, mice injected intravenously with apoptotic cells or DCs22 Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc.fed apoptotic cells are immunized by subcutaneous injection of
antigen on day 2 and then challenged with antigen in the footpad
after an additional 4 days. In both cases, delayed type hypersen-
sitivity (DTH) is measured with a micrometer 1 day (24 hr) after
footpad challenge. The basic design of these systems is illus-
trated in Figure S1 in the Supplemental Data.
Our previous studies have shown that treatment of dying cells
with pharmacologic inhibitors of caspase activation prevent
tolerance induction by apoptotic cells (Ferguson et al., 2002).
To confirm and extend these studies as the basis for the current
work, we employed mouse embryonic fibroblasts (MEFs) that
were either heterozygous (Casp3+/Casp7+/) or null (Casp3/
Casp7/) for the executioner caspases 3 and 7. Although
Casp3/Casp7/ cells die in response to pro-apoptotic stim-
uli, they do not show the apoptosis-associated phenotypes, in-
cluding loss of mitochondrial function [unpublished observations
and (Lakhani et al., 2006)]. Cell death was induced by treatment
with ultraviolet (UV) radiation (see Experimental Procedures),
then fed to TNP-conjugated DCs (TNP-DCs), which were then
injected intravenously. In the experiment shown in Figure 1A,
injection of the TNP-DCs that had engulfed dead, caspase-
heterozygous MEF (Casp3+/Casp7+/) failed to induce immu-
nity to the hapten. In contrast, TNP-DCs that had engulfed dying
MEF deficient in executioner caspases (Casp3/Casp7/) in-
duced immunity as efficiently as did conventional immunization
(immune control). Similarly, mice injected with antigen-coupled
apoptotic splenocytes (spleen cells, g-irrad) did not stimulate
immunity, but g-irradiated spleen cells treated with a caspase
inhibitor (zVAD-fmk) stimulated potent immunity.
Animals injected as above with DCs fed apoptotic MEFs were
also examined for tolerance induction after subcutaneous (s.c.)
immunization with antigen (Figure 1B). Animals treated by injec-
tion of DCs that had engulfed apoptotic, caspase-heterozygous
cells (Casp3+/Casp7+/) were tolerant to subsequent immuni-
zation, whereas those mice given TNP-DCs that had engulfed
UV-irradiated caspase-deficient cells (Casp3/Casp7/)
showed no tolerance. Thus, activation of caspases during apo-
ptosis converts dying cells from potent immunogens (Figure 1A)
to inducers of tolerance (Figure 1B).
ROS Contribute to Tolerance Induction
by Apoptotic Cells
One consequence of caspase activation that depends on MOMP
is the production of ROS by the dying cells as a result of disrupted
electron transport (Ricci et al., 2003; Ricci et al., 2004). We tested
whether such ROS production might contribute to tolerance
induction by apoptotic cells. Antigen-coupled splenocytes were
induced to undergo apoptosis in the presence or absence of the
ROS scavenger butylated hydrozyanisole (BHA). The cells were
then injected intravenously, and animals were immunized subcu-
taneously withantigen 2 days later.Although BHA had no effecton
the extent of cell death (data not shown), it completely prevented
the induction of tolerance by the apoptotic cells (Figure 2A).
Although there are several ways in which ROS could influence
cellular events, an interesting possibility might be that the oxida-
tion of some product of the dying cells affects that product’s
ability to stimulate immune responses and thereby produces
tolerance. To test this idea, we induced antigen-coupled spleen
cells to die by apoptosis (g-irrad) or necrosis (freeze-thaw, F-T)
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Immunity and Tolerance
(A) (Immunogenicity) MEFs deficient in caspases 3
and 7 (Casp3/Casp7/) or heterozygous MEFs
(Casp3+/Casp7+/) were UV irradiated and then
incubated with TNP-DCs overnight. DCs (106)
were then injected intravenously into naive
C57Bl/6 mice. Nx denotes nothing. Spleen cells
were g-irradiated and then incubated for 1 hr
with or without 10 mM zVAD-fmk. They were
then coupled with TNP and injected intravenously
(107) into naive C57Bl/6 mice. Five days after DC
injection, mice were injected with TNBS in the right
footpad and PBS in the left footpad. With the ex-
ception of the immune control, no groups in this
experiment were immunized subcutaneously
with TNBS. Measurements (mm + standard error)
were taken 24 hr later and represent the difference
between the right footpad (antigen challenge) and left footpad (PBS challenge). An asterisk denotes a significant difference from data for unimmunized mice (p <
.01). Data are representative of three independent experiments.
(B) (Tolerogenicity) MEFs deficient in caspases 3 and 7 (Casp3/Casp7/) or heterozygous MEFs (Casp3+/Casp7+/) were UV irradiated and then incubated
with TNP-DCs overnight. DCs (106) were then injected intravenously into naı¨ve C57Bl/6 mice. All mice in this experiment were immunized 2 days later by
subcutaneous injection of TNBS. Four days after immunization, mice were injected with TNBS in the right footpad and PBS in the left footpad. Measurements
(mm + standard error) were taken 24 hr later and represent the difference between the right footpad (antigen challenge) and left footpad (PBS challenge). An
asterisk denotes a significant difference from data for immune control mice (p < .01). Data are representative of three independent experiments.and then treated them with reducing or oxidizing agents before
injecting them into mice. The animals were subsequently immu-
nized subcutaneously, and tolerance was assessed by antigenic
challenge. In the experiment shown in Figure 2B, antigen-coupled
apoptotic cells induced tolerance, whereas antigen-coupled ne-
crotic cells did not. Remarkably, treatment of the apoptotic cells
with the reducing dithiothreitol (DTT) destroyed their ability to
induce tolerance. Conversely, treatment of the necrotic cells with
the oxidant hydrogen peroxide (H2O2) made them tolerogenic.
To extend these observations, we employed mice transgenic
for a membrane-bound ovalbumin (OVA) expressed from the
b-actin promoter (Ehst et al., 2003) as a source of dead cells.
We g-irradiated splenocytes (g-irrad) from Act-mOva mice to in-
duce apoptosis or freeze-thawed (F-T) them to cause necrosis,
then injected them intravenously into wild-type mice. In some
cases the dead cells were treated with DTT or H2O2 prior to injec-
tion. To assess tolerance, we immunized mice by s.c. injection of
OVA in Complete Freund’s adjuvant and 7 days later challenged
them by footpad injection of the soluble OVA. DTH was assessed
24 hr later. Tolerance to OVA was induced by apoptotic, but not
necrotic, Act-mOVA spleen cells (Figure 2C). However, the effect
of apoptotic cells was blocked by treatment with DTT, whereas
necrotic cells treated with H2O2 became tolerogenic for the
associated antigen.
In each case, the treatments with H2O2 or DTT were performed
after the majority of cells had died (6 hr after irradiation, Figure S2).
Therefore, it is likely that the effects were on a molecule that was
in the dead cells and that this molecule is capable of affecting
immune responses, rather than that the effects were on a meta-
bolic process in the dying cell.
Caspase Cleavage of Electron Transport Complex I
in Apoptotic Cells Is Essential for Immune Tolerance
During apoptosis, active executioner caspases gain access to
the mitochondrial intermembrane space as a consequence of
MOMP and there cleave specific substrates. Among them isp75 NDUSF1, a component of complex I of the electron trans-
port chain. As a result of this cleavage event, electron transport,
mitochondrial transmembrane potential, and mitochondrial
structure are all disrupted, and ROS are produced. A single
amino acid substitution in p75 (D to A; called p75D255A or
p75DA) prevents this cleavage and sustains mitochondrial func-
tion in cells undergoing apoptosis (Ricci et al., 2004). We
expressed p75wt or mutant p75DA proteins in HeLa cells and
subjected them to apoptosis induction by UV. ROS production
was dramatically reduced in the cells expressing the mutant
(p75DA) versus the wild-type p75 (p75wt; Figure 3A). Treatment
of UV-irradiated p75wt with zVAD-fmk eliminated ROS produc-
tion (Figure 3A, p75wt-zVAD), demonstrating that the production
of ROS was caspase dependent. Expression of the mutant
p75DA did not influence phosphatidylserine externalization, but
it did delay loss of plasma-membrane integrity in the dying cells
(Figure 3B). Notably, UV-treated p75wt- and p75DA-expressing
cells were engulfed by DCs to the same extent after 2 hr coincu-
bation (p75wt, 36.9% versus p75DA, 32.1%; Figure 3C).
We then examined the consequences of p75 cleavage by cas-
pases on the immunological effects of the dying cells. We treated
HeLa cells expressing p75wt or p75DA with UV to induce apo-
ptosis and then cultured the cells with TNP-DCs. The DCs were
then injected intravenously into mice, and immunity was as-
sessed by challenge 5 days later. Although DCs that had en-
gulfed apoptotic cells expressing p75wt did not induce immunity
to the associated hapten, those that had engulfed apoptotic cells
expressing p75DA effectively primed an anti-hapten response
(Figure 3D). Tolerance induction by DCs that had engulfed apo-
ptotic HeLa cells was then assessed (Figure 3E). Tolerance was
effectively induced by DCs that had engulfed apoptotic HeLa
cells expressing the control p75wt. This tolerance was blocked
if the cells were pretreated with a pan-caspase inhibitor, zVAD-
fmk. However, no tolerance was induced by DCs that had
engulfed apoptotic cells expressing the noncleavable p75DA
mutant. Cleavage of p75 by caspases therefore appears to beImmunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc. 23
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(A) (Tolerogenicity) C57Bl/6 mice were injected intravenously with TNP-cou-
pled apoptotic cells (107) (spleen cells, g-irrad) that were untreated or treated
with 100 mM BHA. Data are representative of three independent experiments.
(B) (Tolerogenicity) C57Bl/6 mice were injected intravenously with TNP-cou-
pled apoptotic cells (spleen cells, g-irrad) (107), apoptotic cells treated with
H2O2 (spleen cells, g-irrad), necrotic cells (F-T) (10
7 equivalence), or necrotic
cells (F-T) treated with DTT. In both experiments (A and B) recipient mice
were immunized subcutaneously with TNBS 2 days later. Four days after
immunization, mice were challenged with TNBS in the right footpad and
PBS in the left footpad. Measurements (mm ± standard error) were taken
24 hr later and represent the difference between the right footpad (antigen
challenge) and left footpad (PBS challenge). Immune control groups were
injected with 0.1 ml 10 mM TNBS subcutaneously. Data are representative
of five independent experiments.
(C) (Tolerogenicity) C57Bl/6 mice were injected intravenously with Act-mOVA
spleen cells (107) (Act-mOVA cells, g-irrad). Two days later, mice were24 Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc.important for the induction of immune tolerance by apoptotic
cells in this system.
Although apoptotic cells expressing p75wt induced tolerance,
a mixture of apoptotic p75wt- and p75DA-expressing apoptotic
cells, fed to DCs, failed to do so (Figure 3F). Therefore, it is likely
that cleavage of p75 by caspases leads to inactivation of an im-
munostimulatory activity in the dying cells and results in toler-
ance induction. Based on our observations with oxidizing and
reducing agents (Figure 2), it is likely that this inactivation is via
ROS resulting from p75 cleavage.
Immunostimulatory HMGB1 Is Released from Apoptotic
Cells with Intact Mitochondria and Low ROS
One of the immunostimulatory molecules implicated in the differ-
ential effects of apoptotic and necrotic cells on the immune sys-
tem is HMGB1. Although necrotic cells release this molecule
upon death, apoptotic cells reportedly do not (Scaffidi et al.,
2002). We speculated that the mitochondrial effects we observed
might influence the release of HMGB1. We found, however, that
supernatants of UV-treated HeLa cells expressing control p75wt
or mutant p75DA had released considerable amounts of HMGB1
into the supernatants by 24 hr (Figure 4A). At an earlier time point
(6 hr), the cells expressing p75DA released less HMGB1, which
was not surprising given the delay in the loss of plasma-mem-
brane integrity in these cells [see Figure 3B and (Ricci et al.,
2004)]. However, by 24 hr substantial amounts of HMGB1 were
present in the supernatants of both cell types.
Remarkably, supernatants of the dying cells expressing
p75DA had a dramatic effect on the ability of apoptotic cells to
induce tolerance. Supernatants from the immunogenic HeLa
cells expressing p75DA (taken 24 hr after induction of apoptosis)
were cocultured with apoptotic splenocytes and TNP-DCs. As
shown in Figure 4B, DCs that had engulfed apoptotic cells in-
duced immune tolerance. However, if the DCs were incubated
with supernatants from the apoptotic cells expressing p75DA
(p75DAs), tolerance induction was abrogated. This effect was
neutralized by the addition of an HMGB1 antibody (aHMGB1)
but not a control antibody (IgG) to the supernatants. Superna-
tants from apoptotic HeLa cells expressing p75wt (p75wts)
had no such effect (Figure 4C). In fact, depleted HMGB1 from
supernatants of the p75DA-expressing cells (which destroyed
the tolerance-abrogating activity) could not be restored by the
addition of supernatants from the p75wt-expressing cells
(p75wts; Figure 4C). Therefore, although HMGB1 appears to
be important in preventing tolerance induction and is released
from cells regardless of p75 status, it appeared that only the
HMGB1 from the cells expressing p75DA had this activity.
To further test the role of HMGB1 in the effects of dying cells
on immunity and tolerance, we employed MEFs from animals
lacking this protein (Figures 4D and 4E). As expected, UV-irradi-
ated wild-type MEFs (Hmgb1+/+) fed to DCs did not promote
immunity unless caspases were inhibited with zVAD-fmk
(Figure 4D). UV-irradiated Hmgb1/ MEFs, however, could
immunized subcutaneously with 100 mg OVA emulsified 1:1 with CFA. Seven
days later, mice were injected with 100 mg heat-aggregated OVA in the right
footpad and PBS in the left footpad. DTH was measured with a micrometer
24 hr later. Data are representative of two independent experiments. An
asterisk denotes a significant difference from immune control mice (p < .01).
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(A) Cells expressing wild-type (p75wt) mutated mitochondrial protein p75 (p75DA) or p75wt cells in the presence of zVAD-fmk were UV irradiated. Cells were
harvested at indicated time points, and ROS production was measured by flow cytometry with DHE. Values are reported as the percentage of cells making
ROS. Data are representative of four independent experiments.
(B) p75wt and p75DA cells were examined at indicated time points after the induction of apoptosis by UV irradiation for PS expression via annexin V and propi-
dium iodide (PI) staining. Numbers in quadrants indicate the percentage of cells.
(C) p75wt and p75DA cells were labeled with PKH26, and DCs were labeled with CFSE. Cells were incubated for 2 hr at 37C and analyzed by flow cytometry.
Data are representative of three independent experiments. Numbers in quadrants indicate the percentage of cells.
(D) (Immunogenicity) Apoptosis was induced in p75wt and p75DA cells by UV irradiation, and these cells were fed to TNP-DCs overnight. DCs were harvested and
injected intravenously (106 per mouse) into recipient mice. Five days later, mice were challenged with TNBS in the right footpad and 0.033 ml PBS in the left foot-
pad. Measurements (mm ± standard error) were taken 24 hr later and represent the difference between the right footpad (antigen challenge) and left footpad (PBS
challenge). Immune control groups were injected with TNBS subcutaneously on the same day as TNP-DC injection. Data are representative of six independent
experiments. An asterisk denotes a signficant differene from data for unimmunized mice (background, Bkg) (p < .01). Data are representative of four independent
experiments (p < .01).
(E) (Tolerogenicity) Apoptosis was induced in p75wt and p75DA cells by UV irradiation, and these cells were fed to TNP-DCs overnight. Some p75wt cells were
treated with 10 mM zVAD-fmk prior to DC culture. DCs were harvested and injected intravenously (106 per mouse) into recipient mice that were immunized
subcutaneously with TNBS 2 days later. Four days after immunization, mice were challenged with TNBS in the right footpad and PBS in the left footpad.
Measurements (mm ± standard error) were taken 24 hr later and represent the difference between the right footpad (antigen challenge) and left footpad (PBS
challenge). Immune control groups were injected with TNBS subcutaneously. Data are representative of five independent experiments. An asterisk denotes a
significant difference from data for immune control mice.
(F) (Tolerogenicity) Apoptosis was induced in p75wt and p75DA cells by UV irradiation, and these cells were fed alone or together to TNP-DCs overnight. Four
days after immunization, mice were challenged with TNBS in the right footpad and PBS in the left footpad. Measurements (mm ± standard error) were taken 24 hr
later and represent the difference between the right footpad (antigen challenge) and left footpad (PBS challenge). Immune control groups were injected with TNBS
subcutaneously. An asterisk denotes a significant difference from data for immune control mice (p < .01). Data are representative of three independent
experiments.not induce immunity regardless of zVAD-fmk addition. Similarly,
UV-irradiated wild-type MEFs induced tolerance (Figure 4E)
unless treated with the reducing agent DTT. In contrast, UV-
irradiated Hmgb1/ MEFs promoted tolerance induction irre-
spective of DTT treatment. Therefore, HMGB1 is central to the
effects on immunity of caspases and ROS in dying cells. In addi-
tion, these results show that the antitolerogenic effect of DTT on
apoptotic cells is due to its action on HMGB1 rather than on the
antigen or some other aspect of antigen presentation.Because a major difference between apoptotic cells express-
ing p75wt and p75DA is the production of ROS in the former (see
Figure 3A), we tested whether oxidation played a role in the
activities of supernatants from these cells. In the experiment
shown in Figure 5A, DCs were again fed with apoptotic cells
and cultured in supernatants from apoptotic p75DA HeLa cells.
Supernatants from apoptotic cells expressing p75DA (p75DAs)
again abrogated the induction of tolerance, whereas superna-
tants from apoptotic cells expressing p75wt (p75wts) did not.Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc. 25
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(A) Cells expressing wild-type p75 (p75wt) or mu-
tated mitochondrial protein p75 (p75DA) were UV
irradiated. Cells were cultured for 6 or 24 hr, and
the supernatants were harvested. HMGB1 was
separated on a reducing SDS-PAGE gel and de-
tected by immunoblotting with a monoclonal
anti-HMGB1.
(B) (Tolerogenicity) Supernatant from p75DA
(p75DAs) was added to TNP-DCs that had been
fed apoptotic spleen cells for 6 hr. In some cases,
polyclonal rabbit anti-HMGB1 (aHMGB1) or con-
trol rabbit IgG (IgG) was added to the supernatant
culture. After overnight culture, DCs were har-
vested and injected intravenously into recipient
mice that were immunized subcutaneously with
TNBS 2 days later. Four days after immunization,
mice were challenged with TNBS in the right
footpad and PBS in the left footpad. Measure-
ments (mm ± standard error) were taken 24 hr later
and represent the difference between the right
footpad (antigen challenge) and left footpad
(PBS challenge). The immune control group was
injected with TNBS subcutaneously. Data are
representative of six independent experiments.
(C) (Tolerogenicity) Supernatants from wild-type
p75 (p75wt) or mutated mitochondrial protein p75
(p75DA) cells were collected 24 hr after UV
irradiation. Supernatants from p75DA (p75DAs)
were treated in various ways before being added
to TNP-DCs that were fed apoptotic spleen cells
for 6 hr. Groups in this experiment were as follows:
immune control, no treatment of DCs (none), P75DA
supernatant treatment only (p75DAs); HMGB1-
depleted p75DAs (-HMGB1); mock depleted with
rabbit IgG (-IgG); p75DAs depleted of HMGB1
with p75wts added back; and p75wts only. After
overnight culture, DCs were harvested and injected
intravenously into recipient mice that were immunized subcutaneously with TNBS 2 days later. Four days after immunization, mice were challenged with TNBS in the
right footpad and PBS in the left footpad. Measurements (mm ± standard error) were taken 24 hr later and represent the difference between the right footpad (antigen
challenge) and left footpad (PBS challenge). Immune control groups were injected with TNBS subcutaneously. An asterisk denotes a significant difference from data
for immune control mice (p < .01). Data are representative of four independent experiments.
(D) (Immunogenicity) HMGB1-deficient MEFs (Hmgb1/) or wild-type control MEFs (Hmgb1+/+) were UV irradiated and then incubated with TNP-DCs overnight.
DCs (13 106) were then injected intravenously into naive C57Bl/6 mice. Five days after DC injection, mice were injected with TNBS in the right footpad and PBS in
the left footpad. With the exception of the immune control, no groups in this experiment were immunized subcutaneously with TNBS. Measurements (mm ± stan-
dard error) were taken 24 hr later and represent the difference between the right footpad (antigen challenge) and left footpad (PBS challenge). An asterisk denotes
a significant difference from data for immune control mice (p < .01). Data are representative of two independent experiments.
(E) Tolerogenicity) HMGB1-deficient MEFs (Hmgb1/) or wild-type control MEFs (Hmgb1+/+) were UV irradiated and then incubated with TNP-DCs overnight.
DCs (1 3 106) were then injected intravenously into naive C57Bl/6 mice. All mice in this experiment were immunized 2 days later by subcutaneous injection of
TNBS. Four days after immunization, mice were injected with TNBS in the right footpad and PBS in the left footpad. Measurements (mm ± standard error) were
taken 24 hr later and represent the difference between the right footpad (antigen challenge) and left footpad (PBS challenge). An asterisk denotes a significant
difference from immune control mice (p < .01). Data are representative of two independent experiments.However, H2O2 destroyed the ability of supernatants from the
p75DA-expressing cells to abrogate tolerance. Conversely, re-
duction of supernatants from apoptotic p75wt-expressing cells
with DTT conferred upon them the ability to block tolerance.
This ability of supernatants from UV-irradiated p75wt cells
treated with DTT to block tolerance induction by apoptotic cells
was dependent on HMGB1 given that the addition of anti-
HMGB1 abrogated this effect (Figure 5B).
Oxidation of Cysteine 106 Inactivates
the Immunostimulatory Activity of HMGB1
Oxidative changes that alter covalent disulfide bonds in HMGB1
have recently been localized to cysteine (C) resides in the protein26 Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc.at positions C23, C45, and C106. Mutation of the C residues to
serine (S) changed the ability of the protein to be affected by
oxidation-reduction (redox) conditions (Hoppe et al., 2006).
Because mutation of cysteines in HMGB1 affect its nuclear local-
ization (Hoppe, et al., 2006), we added recombinant human
HMGB1 (rHMGB1) to DCs that had engulfed apoptotic cells
(Figure 5C). As in our other experiments, DCs that engulfed
apoptotic cells induced tolerance when injected. Culture of
these DCs in DTT-reduced rHMGB1 completely prevented toler-
ance induction, whereas culture with H2O2-oxidized rHMGB1
did not.
We then tested rHMGB1 in which all three cysteines had been
mutated to serine (CS3). Culture of DCs that had engulfed
Immunity
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(A) (Tolerogenicity) Supernatants from wild-type p75 (p75wts) or mutated mi-
tochondrial protein p75 (p75DAs) cells were collected 24 hr after UV irradiation.
Supernatants were treated in various ways before being added to TNP-DCs
that had been fed apoptotic spleen cells for 6 hr. Groups in this experiment
were as follows: immune control, no treatment of DCs (none); p75wts only;
p75DAs only; p75wts treated with DTT; and p75DAs treated with H2O2. Data
are representative of three independent experiments.
(B) (Tolerogenicity) Supernatants from wild-type p75 (p75wts) or mutated mi-
tochondrial protein p75 (p75DAs) cells were collected 24 hr after UV irradiation.
Some supernatant was treated with DTT for 30 min, and anti-HMGB1 or con-
trol IgG was added. Groups in this experiment were control, p75wts only;
p75wts treated with DTT; p75wts treated with DTT with anti-HMGB1 added;
and p75wts treated with DTT with IgG added. Data are representative of three
independent experiments.apoptotic cells with the mutant HMGB1-CS3 potently abrogated
the ability of these DCs to induce tolerance. However, in contrast
to the effects on rHMGB1 activity, addition of either DTT or H2O2
to rHMGB1-CS3 had no effect on its activity. Thus, the redox
status of cysteines in the protein has important consequences
for the ability of HMGB1 to block tolerance induction.
Oxidation of HMGB1 can induce a mobility shift in SDS-PAGE
(Hoppe, et al., 2006), and we have frequently observed the oxi-
dized form of this protein in supernatants of UV-irradiated p75
wild-type cells, but not p75DA cells, when we have analyzed
them in a nonreducing gel (Figure 6A). This presented a paradox
because (1) this effect was not always observed (data not shown)
and (2) even when it was observed, the apparently unmodified
form of HMGB1 was still present in the p75wts (e.g., Figure 6A)
despite a lack of stimulatory activity in the supernatant. How-
ever, oxidation of C106 does not cause such a mobility shift
(Hoppe et al., 2006), and therefore we asked whether this residue
might be critical for the observed effects. We generated rHMGB1
with single serine substitutions at C23 (C23S), C45 (C45S), or
C106 (C106). Addition of the reduced forms of each of these
mutant proteins blocked tolerance induction by apoptotic cells
fed to DCs (Figure 6B). Oxidation of HMGB1C23S or HMGB1C45S
abrogated this effect, whereas oxidation of HMGB1C106S did not.
Thus, oxidation of C106 is necessary and sufficient to inactivate
the immunostimulatory activity of HMGB1.
HMGB1 has been shown to induce maturation of DCs
(Messmer et al., 2004). However, no changes in class II MHC
or CD86 levels were observed in DCs fed apoptotic or necrotic
splenocytes, treated with supernatants from apoptotic p75wt
or p75DA cells, or treated with the low rHMGB1 concentrations
we employed in our studies (Figure S3). Therefore, despite pro-
found effects on immunity and tolerance in vivo, the effects of
HMGB1 on dendritic cell function cannot be readily explained
by overt changes in DC maturation in our system.
DISCUSSION
Immune tolerance is essential for a functioning immune system,
and any approximation of self-nonself discrimination. One way
this occurs is via negative selection during T cell development.
However, tolerance to self-antigens inefficiently presented in
the thymus requires peripheral mechanisms, which also provide
backup should cells escape the central tolerance process. A
plausible mechanism for peripheral tolerance has been pro-
posed whereby steady-state homeostatic cell death (apoptosis)
(C) (Tolerogenicity) Recombinant HMGB1 (rHMGB1) or rHMGB1-CS3 mutant
(CS3; 500 ng/ml each) was added to TNP-DCs that had been fed apoptotic
spleen cells for 6 hr. Groups in this experiment were as follows: immune con-
trol; no treatment of DCs (none); rHMGB1 +DTT; rHMGB1 + H2O2; HMGB1-
CS3 treated with DTT (CS3 + DTT); and HMGB1-CS3 treated with H2O2
(CS3 + H2O2). For (A)–(C), treated DCs were cultured overnight and injected
intravenously into recipient mice that were immunized subcutaneously with
TNBS 2 days later. Four days after immunization, mice were challenged with
TNBS in the right footpad and PBS in the left footpad. Measurements (mm ±
standard error) were taken 24 hr later and represent the difference between
the right footpad (antigen challenge) and left footpad (PBS challenge). Immune
control groups were injected with TNBS subcutaneously. An asterisk denotes
a significant difference from data for immune control mice (p < .01). Data are
representative of two independent experiments.Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc. 27
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than immunity results. Should cell death due to damage or infec-
tion occur, antigen stimulation would be limited only to neoanti-
gens present at the site because tolerance induced by ongoing
apoptosis would eliminate responses to self-antigens (Mat-
zinger, 2002) (Ferguson et al., 2003; Griffith et al., 2007).
During the course of an infection or other insult, the cells of the
host can undergo two general types of cell death: necrosis or
apoptosis. It was originally thought that necrosis stimulates im-
munity but that the immune system is ‘‘blind’’ to apoptotic cells
such that they are cleared from the area without impact on the
immune system (Ferguson and Griffith, 1997). It is now known
that apoptotic cells can stimulate potent immunoregulatory
mechanisms to avert the risk posed by exposure to self-antigens
(Ferguson et al., 2003) (Griffith et al., 2007) (Griffith et al., 1996).
Indeed, apoptotic cells can engender potent immunological tol-
erance to antigens perceived in the context of apoptosis (Griffith
et al., 2007) (Griffith et al., 1996) (Wells et al., 1999). Mechanisms
proposed to account for the tolerogenic nature of apoptotic cells
Figure 6. HMGB1 Function and Cys Modification
(A) Cells expressing wild-type p75 (p75wt) or mutated mitochondrial protein
p75 (p75DA) were UV irradiated. Supernatants were collected for 0–6 hr or
6–24 hr. HMGB1 was separated on a nonreducing SDS-PAGE gel and
detected by immunoblotting with a polyclonal anti-HMGB1.
(B) (Tolerogenicity) Recombinant HMGB1 (rHMGB1), rHMGB1-C23S mutant
(500 ng/ml) rHMGB1-C45S (500 ng/ml) mutant, or rHMGB1-C106S (500 ng/ml)
mutant was treated with DTT or H2O2 and added to TNP-DCs that had been
fed apoptotic spleen cells for 6 hr. After overnight culture, DCs were harvested
and injected intravenously into recipient mice that were immunized subcuta-
neously with TNBS 2 days later. Four days after immunization, mice were chal-
lenged with TNBS in the right footpad and PBS in the left footpad. Measure-
ments (mm ± standard error) were taken 24 hr later and represent the
difference between the right footpad (antigen challenge) and left footpad
(PBS challenge). Immune control groups were injected with TNBS subcutane-
ously. An asterisk denotes a significant difference from data for immune con-
trol mice (p < .01). Data are representative of two independent experiments.28 Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc.include induction of peripheral deletion (Kurts et al., 1998; Stein-
man et al., 2003), anergy [clonal inactivation; (Pape et al., 1998)],
immune deviation [preferential induction of Th2 T cells over Th1;
(Griffith et al., 1996)], and active regulation [Treg or Ts cells;
(Ferguson et al., 2002; Griffith et al., 2007)].
The linkage between apoptosis and tolerance has focused on
DCs because a number of groups have demonstrated that anti-
gens from apoptotic cells are directed to the class I pathway for
cross-priming (or cross-tolerizing) CD8+ T cells (Albert et al.,
2001; Ferguson et al., 2002; Heath et al., 1998; Herndon et al.,
2005). What is not clear is how the apoptotic cells influence the
outcome of the response once they have encountered the
DCs. Several possibilities have been suggested. First, apoptotic
cells might release something that influences the DC population.
Indeed, dying lymphocytes can produce IL-10 (Gao et al., 1998;
Tomimori et al., 2000) and/or TGFb (Chen et al., 2001) during the
process of apoptosis. Although these studies are relevant to lym-
phocytes, it is not clear that all cells can make these cytokines in
response to apoptotic stimuli. A second possibility is that apo-
ptotic bodies might promote tolerance by engaging a receptor
(or receptors) on the surface of the relevant antigen-presenting
cells [e.g., such receptors might include CD36 or phosphytidyl
serine receptors; (Savill et al., 2002)]. Engagement of these re-
ceptors might change the program of the DCs (i.e., immunity to
tolerance) and potentially alter antigen handling and T cell activa-
tion. Recently, it was shown that the loss of certain receptors in-
volved in the removal of apoptotic cells can lead to autoimmunity
(Asano et al., 2004) (Miyanishi et al., 2007). However, it was
recently shown that necrotic cells can induce tolerance if CD4+
T cell-mediated help is abrogated (Griffith et al., 2007). This sug-
gests that specific phagocytic requirements for apoptotic cells
over necrotic cells may not be the only requirement for tolerance.
A third possible mechanism is that engulfed apoptotic bodies
induce the release of anti-inflammatory cytokines from DCs
(Fadok et al., 1998; Ronchetti et al., 1999). A fourth possibility
is that subsets of DCs handle antigen differentially. Indeed, it
was recently shown that tolerogenic CD8a+ DCs present pre-
dominantly via the class I pathway but that CD8a DCs utilize
the class II pathway (Dudziak et al., 2007). This fits with studies
showing that dying cells deliver processed antigen to the class
I pathway of the DCs (Blachere et al., 2005). It also supports
the idea that DC subsets can regulate tolerance or immunity by
apoptotic cells (Ferguson et al., 2002). Here we describe another
mechanism wherein ROS produced in response to caspase
cleavage at the mitochondria neutralize HMGB1 and thereby in-
hibit the influence of this molecule on DCs.
An early model of immune tolerance involved conjugating
antigen to cells and administering them intravenously(Battisto
and Bloom, 1966). More recent studies have shown that the in-
jected cells undergo apoptosis and are ingested by DCs to
cause tolerance (Ferguson et al., 2002). This ability of apoptotic
cells to induce immunological tolerance is dependent on cas-
pase activation in the dying cells (Ferguson et al., 2002; Obeid
et al., 2007b; Tesniere et al., 2008). It is likely that other mech-
anisms support tolerance when the caspase-dependent effects
of apoptotic cells are absent. Our studies presented here show
that the apoptotic cell, and specifically the pathway of apopto-
sis, can have an important influence over the outcome of an
encounter between dead cells and DCs. The production of
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struction leads to the modification of an immunostimulatory
signal that in turn leads to immune tolerance. Thus, apoptosis
provides an additional safeguard to avoid dangerous immune
responses that could result from the release of molecules
from dying cells.
Several mediators have been found to activate DCs to pro-
mote adaptive immunological responses or activate macro-
phages to promote inflammation. These include uric acid (Shi
et al., 2003), calreticulin (Obeid et al., 2007a; Obeid et al.,
2007b), HSP70 (Millar et al., 2003), and HMGB1 (Andersson
et al., 2000; Messmer et al., 2004). Although these mediators
can stimulate immunity, apoptotic cells can inhibit inflammatory
and immunological responses driven by macrophages and DCs
(Fadok et al., 1998). We reasoned that, because apoptosis is tol-
erogenic, mechanisms might be in place to modify these danger
signals during the apoptotic process. Our studies show that neu-
tralization of ROS or prevention of oxidation of HMGB1 by muta-
tion of susceptible cysteines is sufficient to block the induction of
immunological tolerance by apoptotic cells. Whereas our studies
demonstrate that HMGB1 is an important target in our system, it
might not be the only target for ROS affecting immune function.
For example, externalization of calreticulin, which promotes
immunity in response to cell death (including apoptotic cell
death induced by anthracyclins), is regulated by protein phos-
phatases (Obeid et al., 2007b) that can be targets of ROS
(Kamata et al., 2005). Similarly, uric acid is known to be an anti-
oxidant (Haberman et al., 2007), and therefore, its proimmune
functions might be influenced by ROS.
We previously showed that mutation of a conserved caspase
cleavage site in p75 NDUSF1 delays loss of mitochondrial func-
tion during apoptosis and thus sustains ATP in the cell and
delays loss of plasma membrane integrity (Ricci et al., 2004).
Other caspase-dependent events, such as DNA fragmentation,
were unaffected by the mutant p75. Here, we have shown that
ROS production as a consequence of caspase cleavage of
p75 contributes to the immunological effects of apoptotic cells
by oxidation (and thereby neutralization) of HMGB1’s immunos-
timulatory activity. Release of the DNA-binding protein HMGB1
has been shown to be important for several inflammatory condi-
tions, including lipopolysaccaride (LPS)-induced shock (Wang
et al., 1999) and sepsis (Czura and Tracey, 2003). It has been
widely published that HMGB1 is released during necrosis, but
not apoptosis (Scaffidi et al., 2002). However, this idea has re-
cently come into question for several reasons. First, it has
been shown that nuclear DNA and associated proteins are
released in a time-dependent manner during apoptosis (Choi
et al., 2004) and that the binding of HMGB1 to DNA is increased
during apoptosis, consistent with the idea that late-stage apo-
ptotic cells can release both DNA and HMGB1 (Bell et al.,
2006). Studies have also shown that apoptotic tumor cells can
release HMGB1 (Bell et al., 2006; Tian et al., 2007). We have
also found that cells undergoing apoptosis can release substan-
tial levels of HMGB1; however, only HMGB1 released from apo-
ptotic cells that do not make significant ROS is functional in stim-
ulating immune responses. This suggests that a mechanism is in
place to control the potential danger that released HMGB1 could
pose if it leaked from apoptotic cells. Consequently, we would
propose that it is not an inability to release a danger signal thatdetermines whether a cell is tolerogenic but rather that the ability
of the cell to generate oxidative conditions that can destroy dan-
ger signals is paramount. If so, then forms of cell death, including
nonapoptotic cell death, that involve release of ROS might tend
to be tolerogenic rather than immunogenic. At present, such
forms of cell death have not been examined in this way.
It is of interest to note that only oxidation of the C106 of
HMGB1 is required for blocking the protein’s immunogenic func-
tion. This residue lies in the protein’s B-box region, which has
been shown to contain the biological activity. HMGB1 is known
to bind RAGE (receptor for advance glycation end products)
to mediate its effects on macrophage and DC activation
(Andersson et al., 2002; Li et al., 2003; Messmer et al., 2004).
We have not addressed the role of HMGB1’s binding to its
receptor RAGE. Because we do not observe DC maturation in
the presence of rHMGB1 (see Figure S3), we do not know the
role of this receptor in our system. It is important to note that
HMGB1 can bind immunostimulatory cytokines (Sha et al.,
2008), bacterial products (Rouhiainen et al., 2007; Tian et al.,
2007), and many proteins of diverse function (Dintilhac and
Bernues, 2002). This potentially explains many of HMGB1’s
diverse effects on immunity (Andersson et al., 2002; Li et al.,
2003; Messmer et al., 2004), but the role of redox effects on
HMGB1 and that protein’s ability to bind RAGE or other
molecules will require further study.
Other factors might bypass the tolerogenic effects of apopto-
tic cells and/or convert their signals to immunogenic ones.
Recently, we have shown that one way in which apoptotic cells
promote tolerance is by inducing DCs to stimulate CD8+ T cells
in the absence of CD4+ T cell help. The resulting ‘‘helpless’’ CD8+
T cells produce the cytokine TNF-related apoptosis-inducing
ligand (TRAIL) in response to antigenic restimulation and thereby
kill responding T cells and prevent immune responses. For this
reason, TRAIL-deficient animals are not tolerized by antigen-
coupled apoptotic cells. However, if alternative signals were to
stimulate or mimic T cell help, e.g., by stimulating DC maturation,
tolerance would be averted (Griffith et al., 2007). Thus, although
ROS are often associated with inflammatory conditions, other
stimuli that are present in such settings are likely to override
the effects on HMGB1 to promote immunity over tolerance
during inflammation.
EXPERIMENTAL PROCEDURES
Animals
C57Bl/6 (B6) mice were purchased from the National Cancer Institute
(Fredrick, MD). Act-mOVA mice were purchased from Jackson Labs (Bar
Harbor, ME). All animal procedures were performed according to NIH guide-
lines and approved by the Washington University IACUC. Experimental groups
consisted of at least five mice, and each experiment was repeated at least
twice.
Antibodies and Reagents
BHA [2(3)-t-Butyl-4-hydroxyanisole] and TNBS (2,4,6-trinitrobenzene sulfonic
acid) were purchased from Sigma-Aldrich (St. Louis, MO). ZVAD-fmk was pur-
chased from R&D Systems (Minneapolis, MN). A rabbit polyclonal antibody
against HMGB1 was used for HMGB1 neutralization experiments. For produc-
tion of the antibody, rabbits were immunized with synthesized peptide repre-
senting amino acids 166–181 of the human sequence. A monoclonal antibody
against HMGB1 (Sigma-Aldrich, St. Louis, MO) or a polyclonal antibody (BD
Biosciences, San Diego, CA) was used for immunoblotting. FluorescentlyImmunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc. 29
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purchased from BD Biosciences (San Diego, CA). CFA (Complete Freund’s
adjuvant), PKH26, and propidium iodide were purchased from Sigma-Aldrich
(St. Louis, MO).
Cell Lines
HeLa cells expressing a modified NDUFS1 (NADH dehydrogenase Fe-S pro-
tein-1) were used in some experiments. NDUFS1 (called p75 henceforth) is
the 75 kDa subunit of respiratory complex I and is a critical caspase substrate
in the mitochondria. Caspase-3 cleavage of p75 is required for mitochondrial
changes associated with apoptosis. P75wt cells express the wild-type protein
and undergo typical changes after the induction of apoptosis, whereas p75DA
cells express the noncleavable mutant and maintain mitochondrial function
during apoptosis. These cells have been previously described (Ricci et al.,
2004). MEFs deficient in caspases 3 and 7 (Casp3/Casp7/) and heterozy-
gous MEFs deficient in caspases 3 and 7 (Casp3+/Casp7+/) were obtained
from Richard Flavell at Yale University (Lakhani et al., 2006). HMGB1-deficient
MEFs (Hmgb1/) and control MEFs (Hmgb1+/+) were obtained from HMGBio-
tech (Milan, Italy).
Production of Recombinant HMGB1
Recombinant HMGB1 and rHMGB1-CS3 were prepared for in vivo studies.
The CS3 mutant of HMGB1 was made via modification of the C residues at po-
sitions C23, C45 and C106 in human HMGB1 to serine (S) as described (Hoppe
et al., 2006). These modifications prevent oxidation of these sites and the for-
mation of intramolecular disulfide bonds. For creation of recombinant proteins,
CHO cells were transfected with the expression vector containing a histidine
(His)-tagged HMGB1, HMGB1-CS3 (CS3), HMGB1-C23S, HMGB1-C45S,
and HMGB1-C106S by Lipofectamine 2000 (Invitrogen Carlsbad, CA). After
2 days of incubation, cells were lysed in PBS 1% Triton X-100 containing pro-
tease inhibitors. Recombinant HMGB1 was purified with EZview Red HIS-Se-
lect HC Nickel Affinity Gel (Sigma-Aldrich, St. Louis, MO). The beads were
washed with PBS containing 10 mM imidazole. Protein was eluted with PBS
containing 500 mM imidazole, and the eluated material was desalted with a
desalting column. Proteins were used at 500 ng/ml.
Production and Treatment of Apoptotic and Necrotic Cells
Single-cell suspensions of spleen cells were irradiated with 3000 R g-irradia-
tion (apoptotic cells) or made necrotic by five alternating cycles of freeze-thaw-
ing (F-T) and used for intravenous injection. Casp3/Casp7/ MEF cells,
Casp3+/Casp7+/ MEF cells, and HeLa cells (p75wt and p75DA) were irradi-
ated to 800 mJ/cm2 UV irradiation. Plates were treated with trypsin, and cells
were harvested into a single-cell suspension prior to use. In some experi-
ments, apoptotic or necrotic cells were coupled with TNP as described (Fergu-
son et al., 2002) or treated with antioxidant (100 mM BHA), caspase inhibitors
(100 mM zVAD-fmk), DTT (50 mM), or H2O2 (50 mM) prior to intravenous injec-
tion. HeLa cells and MEF cells were first cultured with DCs prior to injection of
DCs intravenously (see below).
Production and Treatment of DCs
Bone-marrow-derived DCs were cultured for 10 days with 10 ng/ml GM-CSF
(Peprotech, Rocky Hill, NJ) in RPMI with 10% FBS. Nonadherent cells were
collected and analyzed by flow cytometry for CD11c expression. Cells were
typically 90%–95% CD11c+. DCs were then coupled with TNP as described
(TNP-DCs) (Ferguson et al., 2002). One million (106) TNP-DCs were mixed
with 53 106 apoptotic spleen cells, 106 apoptotic HeLa cells, or 106 apoptotic
MEFs and incubated overnight. Prior to injection, dead cells were removed by
centrifugation over a Ficoll gradient (GE Healthcare, Piscataway, NJ).
ROS Measurement
Apoptotic cells were stained with 10 mM dihydroethidium (DHE; Invitrogen,
Carlsbad, CA) for 30 min at 37C. Fluorescence intensity was measured by
flow cytometry. Values are reported as the percentage of cells making ROS
as determined by DHE staining.
Preparation and Treatment of Apoptotic Cell Supernatants
For preparation of supernatants from p75wt and p75DA cells, UV-irradiated
cells were cultured for 24 hr at 2 3 106 cells/ml in RPMI-1640 + 10% FBS.30 Immunity 29, 21–32, July 18, 2008 ª2008 Elsevier Inc.Supernatants were used for treating TNP-DCs that were fed apoptotic spleen
cells for 6 hr. In some experiments, supernatants were treated with 50 mM DTT
or 50 mM H2O2 for 30 min on ice. Irradiated apoptotic spleen cells were cul-
tured for 6 hr at 107 cells/ml and then treated with 50 mM DTT or 50 mM
H2O2 for 30 min on ice. After treatment, supernatants were loaded on
a NAP-25 gel column (GE healthcare, Piscataway, NJ) so that excess reagents
would be removed. HMGB1 was neutralized by the addition of 10 mg/ml poly-
clonal rabbit anti-HMGB1 just prior to the addition of the supernatant to DC
cultures. Depletion of HMGB1 from supernatants was accomplished by the
addition of 20mg/ml polyclonal anti-HMGB1 along with protein G-coupled
beads for 30 min on ice. Supernatants were collected by centrifugation.
Depletion was verified by immunoblotting.
Immunological Response
Immunogenicity and tolerogenicity of apoptotic cells were measured with
a well defined in vivo model (Figure S1). Immunogenicity test: TNP-coupled
apoptotic cells (107) or TNP-DCs fed apoptotic cells (106) were injected intra-
venously into mice. Five days later, mice were injected with TNBS in the right
footpad and PBS in the left footpad. DTH was measured with a micrometer
24 hr later. Tolerogenicity test: TNP-coupled apoptotic cells (107) or TNP-
DCs fed apoptotic cells (106) were injected intravenously into mice. Mice
were immunized 2 days later by s.c. injection of TNBS. Four days after immu-
nization, mice were injected with TNBS in the right footpad and PBS in the left
footpad. DTH was measured with a micrometer 24 hr later.
Tolerogenicity of Act-mOVA apoptotic cells was assessed in a manner sim-
ilar to TNP-coupled apoptotic cells. Act-mOVA spleen cells were induced to
undergo apoptosis by g-irradiation, and 107 cells were injected intravenously
into recipient mice. Two days later, mice were immunized subcutaneously with
100 mg OVA emulsified 1:1 with CFA. Seven days later, mice were injected with
100 mg heat-aggregated OVA (1 mg/ml boiled for 5 min) in the right footpad and
PBS in the left footpad. DTH was measured with a micrometer 24 hr later.
Immunoblots
For removal of cellular debris, cell supernatants were centrifuged at 14,000g.
The protein concentration of each sample was determined. Equal amounts of
protein were separated on a reducing or nonreducing 10% Bis-Tris gel (Invitro-
gen, Carlsbad, CA), transferred to nitrocellulose membrane, and blocked with
5% skim milk in TBS/0.05% Tween 20 for 2 hr. The membrane was incubated
with anti-HMGB1 monoclonal antibody or polyclonal rabbit anti-HMGB1 at
4C overnight. After washing, the membrane was incubated with HRP-conju-
gated anti-rabbit antibody in Tris-Tween 20 for 1 hr. After several washes, the
blot was developed by chemiluminescence (ECL-plus; Amersham-Pharmacia,
Piscataway, NJ). Control blots were processed without incubation with the
primary antibody.
Statistical Analysis
Significant differences between groups were evaluated with a two-tailed
Student’s t test (p < 0.01).
SUPPLEMENTAL DATA
Supplemental Data include three supplemental figures and can be found
with this article online at http://www.immunity.com/cgi/content/full/29/1/21/
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